Agilent Technologies Inc. has introduced SurePrint G3 CGH+SNP cancer catalog microarrays, addressing the growing need of researchers to detect both copy number and copy-neutral aberrations in cancer ...
Three genomic tests separately predict the likelihood that a patient's breast cancer will reoccur after surgery without additional treatment, and the cancer's vulnerability to chemotherapy or hormone ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する